Get the Stockscreener App
3.0266
2.27%
-0.0534
Heartsciences Inc stock is traded at $3.0266, with a volume of 795.
It is down -2.27% in the last 24 hours and up +12.73% over the past month.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
See More
Previous Close:
$3.08
Open:
$3.11
24h Volume:
795
Relative Volume:
0.02
Market Cap:
$9.57M
Revenue:
-
Net Income/Loss:
$-7.29M
P/E Ratio:
-0.1242
EPS:
-24.3686
Net Cash Flow:
$-6.81M
1W Performance:
+1.18%
1M Performance:
+12.73%
6M Performance:
-15.69%
1Y Performance:
-17.53%
1-Day Range:
$3.01
$3.11
1-Week Range:
$2.95
$3.21
52-Week Range:
$2.01
$6.47
Heartsciences Inc Stock (HSCS) Company Profile
Name
Heartsciences Inc
Sector
Industry
Phone
682-237-7781
Address
550 RESERVE ST, SUITE 360, SOUTHLAKE
Compare HSCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSCS
Heartsciences Inc
|
3.01 | 9.98M | 0 | -7.29M | -6.81M | -24.37 |
|
ABT
Abbott Laboratories
|
128.32 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.31 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.47 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.58 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Heartsciences Inc Stock (HSCS) Latest News
What analysts say about HeartSciences Inc Equity Warrant stockMarket Depth Overview & Free Technical Analysis and Insights - earlytimes.in
Market Meltdown the Virus and our ActionablesStock Price Divergence & Affordable Trading Strategies - bollywoodhelpline.com
Indo Count Industries Limited (ICIL) Expands into New MarketPrice-to-Book Ratio Updates & Exceptional Capital Growth - bollywoodhelpline.com
HeartSciences (NASDAQ:HSCS) Price Target Raised to $9.20 at Ascendiant Capital Markets - Defense World
HeartSciences (NASDAQ:HSCS) and Movano (NASDAQ:MOVE) Critical Survey - Defense World
Why HeartSciences Inc. Equity Warrant stock remains resilient2025 Momentum Check & AI Forecasted Stock Moves - DonanımHaber
Ascendiant Capital Maintains HeartSciences (HSCS) Buy Recommendation - Nasdaq
HeartSciences (HSCS) Receives Updated Analyst Rating and Price T - GuruFocus
Is HeartSciences Inc. Equity Warrant stock a top pick in earnings seasonMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis - Defense World
Does HeartSciences Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Why HeartSciences Inc. Equity Warrant stock could see breakout soon2025 Sector Review & Fast Entry High Yield Tips - Улправда
Is HeartSciences Inc. stock a safe haven assetQuarterly Market Review & Comprehensive Market Scan Insights - Bölüm Sonu Canavarı
Will HeartSciences Inc. Equity Warrant stock attract ESG investorsMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
Will HeartSciences Inc. Equity Warrant stock recover faster than peersJuly 2025 Final Week & Growth Focused Stock Pick Reports - DonanımHaber
Will HeartSciences Inc. Equity Warrant stock deliver shareholder valueJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Is HeartSciences Inc. Equity Warrant stock supported by strong cash flowsEntry Point & Comprehensive Market Scan Reports - Улправда
History Review: Does HeartSciences Inc. stock trade at a discount to peers2025 Major Catalysts & Real-Time Volume Triggers - Улправда
HeartSciences Submits MyoVista wavECG Device for FDA Clearance - Diagnostic and Interventional Cardiology
HeartSciences approves indemnification agreements for directors and officers By Investing.com - Investing.com Nigeria
HeartSciences approves indemnification agreements for directors and officers - Investing.com
Heart Test Laboratories Approves Indemnification Agreement - TipRanks
HeartSciences reports no meaningful revenue in Q2 2026 - Medical Buyer
HeartSciences Inc. Reports Second Quarter Fiscal 2026 Financial Results and Progress on MyoVista Insights and wavECG Device Submissions - Quiver Quantitative
HeartSciences (Nasdaq: HSCS) Q2 shows $2M cash, MyoVista Insights push - Stock Titan
HeartSciences (NASDAQ: HSCS) posts loss, highlights going concern and new funding - Stock Titan
HeartSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025 - marketscreener.com
HeartSciences files FDA 510(k) for MyoVista WaveCG device - marketscreener.com
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - The Manila Times
HeartSciences (Nasdaq: HSCS) separates device, AI-ECG FDA paths - Stock Titan
HeartSciences Inc. Announces Commercial Release of MyoVista Insights™ Version 1.1 Enhancing ECG System Capabilities - Quiver Quantitative
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with ... - Enidnews.com
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 - The Manila Times
HeartSciences Announces Major Upgrade to User Features of - GlobeNewswire
HeartSciences (Nasdaq: HSCS) rolls out MyoVista Insights 1.1 to enhance ECG workflows - Stock Titan
Gross profit of HeartSciences Inc. from 2021 to 2024 - Statista
HeartSciences (HSCS) to Release Quarterly Earnings on Monday - Defense World
Reviewing Hims & Hers Health (NYSE:HIMS) and HeartSciences (NASDAQ:HSCS) - Defense World
S&P 500, NASDAQ and Dow continue upward trend as Wall Street rises to the edge of its all-time high; Treas - The Economic Times
Risk Off: Why MLPR stock is seen as undervaluedPrice Action & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
How HeartSciences Inc. Equity Warrant stock performs in rate cut cyclesJuly 2025 Levels & Weekly Return Optimization Alerts - Newser
HeartSciences (HSCSW) Stock Analysis Report | Financials & Insights - Benzinga
Will HeartSciences Inc. Equity Warrant stock keep outperforming rivalsJuly 2025 Momentum & Reliable Intraday Trade Alerts - Newser
How HeartSciences Inc. stock performs after earningsJuly 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
HeartSciences (HSCS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CapEx per share of HeartSciences Inc. Warrant 2022- on Heart Test Lab Rg – NASDAQ:HSCSW - TradingView
HeartSciences (NASDAQ:HSCS) and Tempus AI (NASDAQ:TEM) Financial Survey - Defense World
HeartSciences (HSCS) Stock Price, Quote, News & History - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why HeartSciences Inc. stock is a must watch in 2025Quarterly Market Review & Daily Price Action Insights - newser.com
Why HeartSciences Inc. stock is favored by pension fundsTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Heartsciences Inc Stock (HSCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):